Irritable Bowel Syndrome - Pipeline Review, H2 2016
|
|
- Susanna May
- 6 years ago
- Views:
Transcription
1 Published on Market Research Reports Inc. ( Home > Irritable Bowel Syndrome - Pipeline Review, H Irritable Bowel Syndrome - Pipeline Review, H Publication ID: GMD Publication November 16, 2016 Date: Pages: 140 Publisher: Global Markets Direct Countries: Global [1] $2, Publication License Type * SINGLE USER LICENSE (PDF), $2, SITE LICENSE (PDF), $4, GLOBAL LICENSE (PDF), $6, Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
2 Add to cart Diseases [2] Pharma & Healthcare [3] Description: Irritable Bowel Syndrome - Pipeline Review, H Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome Pipeline Review, H2 2016, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape. Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.irritable Bowel Syndrome. Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking
3 emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies.
4 - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Table Of Contents: Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Irritable Bowel Syndrome Overview 10 Therapeutics Development 11 Pipeline Products for Irritable Bowel Syndrome - Overview 11 Irritable Bowel Syndrome - Therapeutics under Development by Companies 12 Irritable Bowel Syndrome - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Irritable Bowel Syndrome - Products under Development by Companies 17 Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 19 4D Pharma Plc 19 A. Menarini Industrie Farmaceutiche Riunite Srl 20 Alfa Wassermann S.p.A 21 Ardelyx, Inc. 22 Astellas Pharma Inc. 23 CJ HealthCare Corp. 24 Dong-A Socio Holdings Co. Ltd. 25 Enterome Bioscience SA 26 GlaxoSmithKline Plc 27 Innovative Med Concepts, LLC 28 Ironwood Pharmaceuticals, Inc. 29 Kissei Pharmaceutical Co., Ltd. 30 Lexicon Pharmaceuticals, Inc. 31
5 Napo Pharmaceuticals Inc 32 Ono Pharmaceutical Co., Ltd. 33 Pfizer Inc. 34 RaQualia Pharma Inc. 35 RedHill Biopharma Ltd. 36 SK Biopharmaceuticals Co., Ltd. 37 Sumitomo Dainippon Pharma Co Ltd 38 Synergy Pharmaceuticals, Inc. 39 Synthetic Biologics, Inc. 40 Vitality Biopharma Inc 41 Irritable Bowel Syndrome - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Combination Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 (celecoxib + famciclovir) - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ASP Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 ASP Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 bedoradrine sulfate - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Blautix - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 CJ Drug Profile 60 Product Description 60
6 Mechanism Of Action 60 R&D Progress 60 crofelemer DR - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 CSTI Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 DA Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 DSP Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 EB Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 GSK Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 ibodutant - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 linaclotide - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 lovastatin - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 LT Drug Profile 81 Product Description 81
7 Mechanism Of Action 81 R&D Progress 81 LX Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 ondansetron hydrochloride CR - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 ONO Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 ORP Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 PBF Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 plecanatide - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 pregabalin - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 relenopride hydrochloride - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 rifaximin - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 RQ Drug Profile 109 Product Description 109
8 Mechanism Of Action 109 R&D Progress 109 RQ Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 solabegron hydrochloride - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 tenapanor hydrochloride - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 VB Drug Profile 119 Product Description 119 Mechanism Of Action 119 R&D Progress 119 Irritable Bowel Syndrome - Dormant Projects 120 Irritable Bowel Syndrome - Discontinued Products 125 Irritable Bowel Syndrome - Product Development Milestones 126 Featured News & Press Releases 126 Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 126 Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting 127 Oct 17, 2016: Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology Annual Scientific Meeting 128 Sep 28, 2016: Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program 129 Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation 130 Jul 19, 2016: 4D Pharma Provides Phase I Clinical Trial Update 130 Jul 15, 2016: Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program 131 Jun 20, 2016: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA for
9 IBS-D 132 May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the ph-dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin 133 May 23, 2016: Phase I trial Update On Blautix For The Treatment Of Irritable Bowel Syndrome : 4D pharma 133 May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 134 May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 136 May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development 137 Appendix 139 Methodology 139 Coverage 139 Secondary Research 139 Primary Research 139 Expert Panel Validation 139 Contact Us 139 Disclaimer 140 List of Tables Number of Products under Development for Irritable Bowel Syndrome, H Number of Products under Development by Companies, H Number of Products under Development by Companies, H (Contd..1) 13 Comparative Analysis by Late Stage Development, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Development, H Products under Development by Companies, H Products under Development by Companies, H (Contd..1) 18 Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp., H Irritable Bowel Syndrome - Pipeline by Dong-A Socio Holdings Co. Ltd., H
10 Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts, LLC, H Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co., Ltd., H Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals, Inc., H Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H Irritable Bowel Syndrome - Pipeline by Pfizer Inc., H Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd., H Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H Assessment by Monotherapy Products, H Assessment by Combination Products, H Number of Products by Stage and Target, H Number of Products by Stage and Mechanism of Action, H Number of Products by Stage and Route of Administration, H Number of Products by Stage and Molecule Type, H Irritable Bowel Syndrome - Dormant Projects, H Irritable Bowel Syndrome - Dormant Projects (Contd..1), H Irritable Bowel Syndrome - Dormant Projects (Contd..2), H Irritable Bowel Syndrome - Dormant Projects (Contd..3), H Irritable Bowel Syndrome - Dormant Projects (Contd..4), H Irritable Bowel Syndrome - Discontinued Products, H List of Figures Number of Products under Development for Irritable Bowel Syndrome, H Number of Products under Development by Companies, H Comparative Analysis by Late Stage Development, H Comparative Analysis by Clinical Stage Development, H Comparative Analysis by Early Stage Products, H Assessment by Monotherapy Products, H Number of Products by Top 10 Targets, H Number of Products by Stage and Top 10 Targets, H Number of Products by Top 10 Mechanism of Actions, H Number of Products by Stage and Top 10 Mechanism of Actions, H
11 Number of Products by Routes of Administration, H Number of Products by Stage and Routes of Administration, H Number of Products by Molecule Types, H Number of Products by Stage and Molecule Types, H Companies Mentioned: 4D Pharma Plc A. Menarini Industrie Farmaceutiche Riunite Srl Alfa Wassermann S.p.A Ardelyx, Inc. Astellas Pharma Inc. CJ HealthCare Corp. Dong-A Socio Holdings Co. Ltd. Enterome Bioscience SA GlaxoSmithKline Plc Innovative Med Concepts, LLC Ironwood Pharmaceuticals, Inc. Kissei Pharmaceutical Co., Ltd. Lexicon Pharmaceuticals, Inc. Napo Pharmaceuticals Inc Ono Pharmaceutical Co., Ltd. Pfizer Inc. RaQualia Pharma Inc. RedHill Biopharma Ltd. SK Biopharmaceuticals Co., Ltd. Sumitomo Dainippon Pharma Co Ltd Synergy Pharmaceuticals, Inc. Synthetic Biologics, Inc. Vitality Biopharma Inc License Types: Single User License (PDF) This license allows for use of a publication by one person. This person may print out a single copy of the publication. This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. This person cannot share the publication (or any information contained therein) with any other person or persons.
12 Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Site License (PDF)* This license allows for use of a publication by all users within one corporate location, e.g. a regional office. These users may print out a single copy of the publication. These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased. Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Global License (PDF)* This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company. Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization. These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. *If Applicable. Source URL: Links [1] [2] [3]
Irritable Bowel Syndrome - Pipeline Review, H2 2016
Report Information More information from: https://www.wiseguyreports.com/reports/752817-irritable-bowel-syndrome-pipeline-review-h2-2016 Irritable Bowel Syndrome - Pipeline Review, H2 2016 Report / Search
More informationAdrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder- Addison Complex) - Pipeline Review, H2 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2016 Adrenoleukodystrophy
More informationCognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Cognitive Impairment Associated
More informationDiabetic Peripheral Neuropathy - Pipeline Review, H2 2017
Published on Drug Pipeline (https://www.drugpipeline.net) Home > Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017 Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017 Publication ID: GMD0717059
More informationMild Cognitive Impairment - Pipeline Review, H1 2017
Report Information More information from: https://www.wiseguyreports.com/reports/1184709-mild-cognitive-impairment-pipeline-review-h1-2017 Mild Cognitive Impairment - Pipeline Review, H1 2017 Report /
More informationAtrial Fibrillation - Pipeline Review, H1 2017
Report Information More information from: https://www.wiseguyreports.com/reports/1095866-atrial-fibrillation-pipeline-review-h1-2017 Atrial Fibrillation - Pipeline Review, H1 2017 Report / Search Code:
More informationDravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016 BioPortfolio has been marketing business
More informationHuman Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business
More informationDiabetic Neuropathy - Pipeline Review, H1 2017
Diabetic Neuropathy - Pipeline Review, H1 2017 Diabetic Neuropathy - Pipeline Review, H1 2017 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen
More informationHuman Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016
Report Information More information from: https://www.wiseguyreports.com/reports/685904-human-papillomavirus-hpv-associated-cancerpipeline-review-h2-2016 Human Papillomavirus (HPV) Associated Cancer -
More informationRecurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016 Recurrent Glioblastoma Multiforme (GBM) - Pipeline
More informationGlobal Patient Scales Market Research Report 2021
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Patient Scales Market Research Report 2021 Global Patient Scales Market Research Report 2021 Publication
More informationSpinal Cord Injury - Pipeline Review, H2 2016
Spinal Cord Injury - Pipeline Review, H2 2016 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service
More informationGlobal Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016 Global Magnetic Resonance Imaging (MRI)
More informationGlobal Standard Radiography Film X-Ray Film Printer Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Standard Radiography Film X-Ray Film Printer Market Research Report 2016 Global Standard Radiography Film
More informationEurope Ginseng Market Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Europe Ginseng Market Report 2016 Europe Ginseng Market Report 2016 Publication ID: QYR12167206 Publication December
More informationDiabetic Retinopathy Treatment - Global Market Outlook ( )
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022) Diabetic Retinopathy Treatment - Global Market
More informationGlobal Oil Softgel Capsules Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oil Softgel Capsules Market Research Report 2016 Global Oil Softgel Capsules Market Research Report 2016
More informationGlobal Massage Oil Market Research Report 2021
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Massage Oil Market Research Report 2021 Global Massage Oil Market Research Report 2021 Publication ID: QYR08160227
More informationUnited States Tuberculosis Vaccine Industry 2016 Market Research Report
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > United States Tuberculosis Vaccine Industry 2016 Market Research Report United States Tuberculosis Vaccine Industry
More informationMexico Milling Machine for Dental Clinics Industry 2016 Market Research Report
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Mexico Milling Machine for Dental Clinics Industry Market Research Report Mexico Milling Machine for Dental Clinics
More informationChina Dental Implants Market Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > China Dental Implants Market Report 2016 China Dental Implants Market Report 2016 Publication ID: QYR101600170 Publication
More informationGlobal Hearing Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast to 2022
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Hearing Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company
More informationContinuous Renal Replacement Therapy (CRRT) - Global Market Outlook ( )
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Continuous Renal Replacement Therapy (CRRT) - Global Market Outlook (2015-2022) Continuous Renal Replacement Therapy
More informationUnited States NDT System Market Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > United States NDT System Market Report 2016 United States NDT System Market Report 2016 Publication ID: QYR091604895
More informationGlobal Chymosin Market Research Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Chymosin Market Research Report 2016 Global Chymosin Market Research Report 2016 Publication ID: QYR101602046
More informationGlobal Vitamin Market Professional Survey Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Vitamin Market Professional Survey Report 2016 Global Vitamin Market Professional Survey Report 2016 Publication
More informationWhole Grain and High Fiber - Global Market Outlook ( )
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Whole Grain and High Fiber - Global Market Outlook (2015-2022) Whole Grain and High Fiber - Global Market Outlook
More informationUnited States Antimony Tin Oxide Nanoparticles Market Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > United States Antimony Tin Oxide Nanoparticles Market Report 2016 United States Antimony Tin Oxide Nanoparticles
More informationEurope Tooth Shade Scanners Industry 2016 Market Research Report
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Europe Tooth Shade Scanners Industry Market Research Report Europe Tooth Shade Scanners Industry Market Research
More informationGlobal Otoscopes Market Professional Survey Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Otoscopes Market Professional Survey Report 2016 Global Otoscopes Market Professional Survey Report 2016
More informationCochlear Implants - Medical Devices Pipeline Assessment, 2016
Cochlear Implants - Medical Devices Pipeline Assessment, 2016 Cochlear Implants - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been marketing business and market research reports from selected
More informationGlobal Nutraceuticals Market
Published on NOVONOUS (https://www.novonous.com) Home > Global Nutraceuticals Market 2016-2020 Global Nutraceuticals Market 2016-2020 Publication ID: NOV1016004 Publication Date: October 14, 2016 Pages:
More informationPercutaneous Transluminal Angioplasty Balloons - Medical Devices Pipeline Assessment, 2016
Percutaneous Transluminal Angioplasty Balloons - Medical Devices Pipeline Assessment, 2016 Percutaneous Transluminal Angioplasty Balloons - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been
More informationPress Release. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D
Press Release RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D Top-line results are expected in the third quarter of 2017 The randomized, double-blind, placebo-controlled
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationREFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME Executive Summary Sales of Irritable Bowel Syndrome Market The Irritable Bowel Syndrome (IBS) market in the 7MM (US,
More informationGlobal and China Humic Acid Research Report to 2020
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global and China Humic Acid Research Report to 2020 Global and China Humic Acid Research Report to 2020 Publication
More informationGlobal Glycerol Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Competitive Scenario And Forecasts, 2012 To 2020
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Glycerol Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Competitive Scenario
More informationAesthetic Laser - Medical Devices Pipeline Assessment, 2016
Aesthetic Laser - Medical Devices Pipeline Assessment, 2016 Aesthetic Laser - Medical Devices Pipeline Assessment, 2016 BioPortfolio has been marketing business and market research reports from selected
More informationH. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationNon Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018
Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase
More informationChemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016
Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H1, 2016 BioPortfolio has been marketing business
More informationWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
More informationChina Dermatology Laser Industry Report 2015
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > China Dermatology Laser Industry Report 2015 China Dermatology Laser Industry Report 2015 Publication ID: QYR031605014
More informationU.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon),
U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin,
More informationPress Release. RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D
Press Release RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D Based on recent U.S. FDA feedback and prior feedback
More informationARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C
ARDELYX REPORTS POSITIVE T3MPO-2 PHASE 3 TRIAL RESULTS IN IBS-C OCTOBER 11, 2017 NASDAQ: ARDX FORWARD-LOOKING STATEMENTS To the extent that statements contained in this presentation are not descriptions
More informationDravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2015 BioPortfolio
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationReport Information. Shoulder Replacement - Pipeline Review, 2015
Report Information Shoulder Replacement - Pipeline Review, 2015 Report / Search Code: WGR178241 Publish Date: 4 September, 2015 Report Price: 1-user PDF : $ 2500.0 Site PDF : $ 5000.0 Enterprise PDF :
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationGlobal Margarine Market Professional Survey Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Margarine Market Professional Survey Report 2016 Global Margarine Market Professional Survey Report 2016
More information(39% 20%), (36% 20%) (36% 17%) MAP US,
Press Release RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn s Disease at United European Gastroenterology (UEG) Week 2018 The presentation highlighted enhanced
More informationInsulin Pens - Medical Devices Pipeline Assessment, 2016
Insulin Pens - Medical Devices Pipeline Assessment, 2016 Insulin Pens - Medical Devices Pipeline Assessment, 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business and market research
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationREFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of AstraZeneca/Ardelyx s tenapanor for Irritable
More informationPress Release. YELIVA, a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the treatment of cholangiocarcinoma
Press Release RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA ) for Cholangiocarcinoma at Mayo Clinic and MD Anderson YELIVA, a proprietary, first-in-class SK2 inhibitor,
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Almirall Contact: Susan Brady Ketchum Pleon Corporate Communications Amanda Sefton 617.621.8304 +44 (0) 207.611.3653 sbrady@ironwoodpharma.com amanda.sefton@ketchumpleon.com
More informationREFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - Executive Summary The Table below presents the key metrics of Ironwood/Actavis/Almirall/Astellas Linzess for
More informationBariatric Surgery Devices - North America Analysis and Market Forecasts
Bariatric Surgery Devices - North America Analysis and Market Forecasts Bariatric Surgery Devices - North America Analysis and Market Forecasts BioPortfolio has been marketing business and market research
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationREFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Furiex (Actavis) s eluxadoline for Irritable
More informationPress Release. RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal
Press Release RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal RedHill and Concordia entered into an exclusive co-promotion agreement, granting RedHill
More informationOphthalmology Drug Development Pipeline Review, 2016
Ophthalmology Drug Development Pipeline Review, 2016 Ophthalmology Drug Development Pipeline Review, 2016 BioPortfolio has been marketing business and market research reports from selected publishers for
More informationRenal Denervation Catheters - Medical Devices Pipeline Assessment, 2017
Renal Denervation Catheters - Medical Devices Pipeline Assessment, 2017 Renal Denervation Catheters - Medical Devices Pipeline Assessment, 2017 The Business Research Store is run by Sector Publishing Intelligence
More informationDry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013
Dry Eye Syndrome - Current and Future Players GDHC1016FPR / Published May 2013 Executive Summary Significant growth is expected in the DES market from 2012-2022. GlobalData estimates 2012 DES therapeutic
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationTandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile
Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationMexico Ostomy Drainage Bags Market Outlook to 2020
Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
More informationREFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Prometheus Lotronex for irritable bowel syndrome
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationCompetitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment
Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment Competitor Analysis: IDO & TDO Inhibitors for Modulation of the Tumor Microenvironment BioPortfolio has been marketing
More informationCompetitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment
Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment Competitor Analysis: TGF-? Inhibitors for Modulation of the Tumor Microenvironment BioPortfolio has been marketing business
More informationSAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationeclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " Projected to grow at a CAGR of around 12%, eclinical solutions market is expected to witness significant
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationRelief, true to form
For adults with Chronic Idiopathic Constipation (CIC) or Irritable Bowel Syndrome with Constipation (IBS-C) Relief, true to form When It Comes to Constipation Relief, Form Matters Trulance can help you
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationCallisto Pharmaceuticals Amex: KAL. Rodman & Renshaw Investor Conference November 7, 2007 Gary S. Jacob, Ph.D., CEO
Callisto Pharmaceuticals Amex: KAL Rodman & Renshaw Investor Conference November 7, 2007 Gary S. Jacob, Ph.D., CEO CALLISTO PHARMACEUTICALS, INC. Certain statements made in this presentation are forward-looking.
More informationRussia Cardiac Assist Devices Market Outlook to 2021
Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 BioPortfolio has been marketing business and market research reports from selected publishers for
More informationSickle-cell Anemia Therapeutics Market in the US
Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sickle-cell Anemia Therapeutics Market in the US 2015-2019 Sector Publishing Intelligence Limited (SPi) has been marketing business and market
More informationChina Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationHearing Aid Devices - Medical Devices Pipeline Assessment, 2018
Hearing Aid Devices - Medical Devices Pipeline Assessment, 2018 #1686307 $2500 147 pages In Stock Report Description Hearing Aid Devices - Medical Devices Pipeline Assessment, 2018 Summary GlobalData's
More informationNoninvasive Glucose Monitors to 2022
Noninvasive Glucose Monitors to 2022 Devices, Technologies, Players and Prospects Report Prospectus Greystone Research associates N o n i n v a s i v e G l u c o s e M o n i t o r s t o 2 0 2 2 Greystone
More informationNEWSLETTER June Summer greetings from Follicum
NEWSLETTER June 2018 Follicum hopes that this newsletter reaches as many of the company's owners and stakeholders as possible. If you wish to follow our continued development, please register your e-mail
More information- Amendment accelerates anticipated PROSPER top-line results by two years -
Pfizer Contacts: For Media Dean Mastrojohn (212) 733-6944 dean.mastrojohn@pfizer.com For Investors Ryan Crowe (212) 733-8160 ryan.crowe@pfizer.com Astellas Contact: For Media Tyler Marciniak (847) 736-7145
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationOncology Therapeutics Market in India to 2018
Oncology Therapeutics Market in India to 2018 Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players GBI Research Report Guidance GBI Research
More informationSAMPLE. North America Propylene Industry Outlook to 2017 GDCH0615RDB/JAN 2013
- Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants Reference Code: GDCH0615RDB Publication Date: January 2013 GlobalData. This report is a licensed product
More informationCyclokat (Dry Eye Syndrome)
Cyclokat (Dry Eye Syndrome) Forecast and Market Analysis to 2022 GDHC191DFR / Published July 2013 Executive Summary Below table provides a summary of the key metrics for Cyclokat in the major pharmaceuticals
More information